SCHEMBL7447684

SCHEMBL7447684

O=C1C=CC=CCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89327 0.80
Methane SCHEMBL595114 0.78
Hydrochloric Acid SCHEMBL27731613 0.78
SCHEMBL29053757 0.72 GSK3A (0.55)
SCHEMBL18324454 0.67
SCHEMBL1035336 0.66
SCHEMBL13584912 0.65
SCHEMBL11816980 0.64 GSK3A (0.41)
SCHEMBL586833 0.64
SCHEMBL3675360 0.61 GSK3A (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0267277-A4 COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS. NELSON RES & DEV COMPANY (US) 1990-03-21 EP claimed
US-4755535-A Compositions comprising 1-substituted azacycloalkenes NELSON RESEARCH & DEVELOPMENT CO. (US) 1988-07-05 US claimed
EP-0267277-A1 COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS. NELSON RES & DEV (US) 1988-05-18 EP claimed
WO-1987006583-A1 COMPOSITIONS COMPRISING 1-SUBSTITUTED LACTAMS NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1987-11-05 WO claimed
WO-2022210479-A1 USE OF AZEPANE DERIVATIVE FOR TREATMENT, AMELIORATION OR PREVENTION OF κ-OPIOID RECEPTOR-RELATED DISEASES 日本ケミファ株式会社 2022-10-06 WO disclosed
CN-106957305-B Alkaloid compound in anabasine root and preparation method thereof 中国科学院新疆理化技术研究所 2022-08-30 CN disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
US-9688644-B2 Synthesis of Tetracyclines and intermediates thereto PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-06-27 US disclosed
EP-3138831-A1 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF President and Fellows of Harvard College (US) 2017-03-08 EP disclosed
US-9301957-B2 Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation NOVARTIS AG (CH) 2016-04-05 US disclosed
EP-2651916-A2 C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 BioMarin Pharmaceutical Inc. (US) 2013-10-23 EP disclosed
WO-2012083112-A2 CYP11B, CYP17, AND/OR CYP21 INHIBITORS BIOMARIN PHARMACEUTICAL INC. (US) 2012-06-21 WO disclosed
WO-1998005664-A1 6,7,8,9-TETRAHYDRO-5H-IMIDAZO[1,2-a]AZEPINE-3-ACETIC ACID DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF SYNTHELABO (FR) 1998-02-12 WO disclosed
EP-0299663-A2 Antihistaminic aromatic tetrahydroazepinones (and thiones) A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1989-01-18 EP disclosed